Compare BIT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIT | DNA |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.0M | 562.3M |
| IPO Year | N/A | N/A |
| Metric | BIT | DNA |
|---|---|---|
| Price | $13.16 | $9.39 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 92.4K | ★ 979.7K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,606,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.65 | $5.00 |
| 52 Week High | $15.97 | $17.58 |
| Indicator | BIT | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 47.51 |
| Support Level | $13.10 | $8.56 |
| Resistance Level | $13.29 | $10.05 |
| Average True Range (ATR) | 0.08 | 0.55 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 45.99 | 65.25 |
BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loan and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities, and others.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.